STAT+: Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Image Credit: STAT News

STAT+: Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda

Watchdoq April 25, 2025
An Akeso lung cancer drug that beat Merck’s Keytruda in a head-to-head trial won approval in China this week

Read Full Article